Tang et al. [63] demonstrated that targeting CD44 with anti-CD44s monoclonal antibody H4C4 in pancreatic cancer significantly inhibits tumor growth, metastasis, and recurrence, with substantial in vitro and in vivo effects on cancer stem cells, highlighting its potential as a therapeutic agent. The gene discussed is CD44; the disease is pancreatic neoplasm.